Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Aug;17(4):214-20.
doi: 10.1111/j.1755-5949.2010.00139.x. Epub 2010 Apr 8.

Acute administration of benzodiazepines as part of treatment strategies for epilepsy

Affiliations
Clinical Trial

Acute administration of benzodiazepines as part of treatment strategies for epilepsy

Peter Wolf. CNS Neurosci Ther. 2011 Aug.

Abstract

Ad-hoc administration of benzodiazepines (BZD) is well established in status epilepticus, but intermittent BZD use in the treatment of chronic epilepsy is little known beyond catamenial epilepsy. We aim to assess the use of acute drug administration (ADA) in the treatment of 24 patients with epilepsy (9 idiopathic generalized, 14 focal symptomatic/cryptogenic, 1 migraine-epilepsy) receiving ADA for (1) prevention of generalized tonic-clonic seizures (GTCS) after minor seizures, (2) prevention of seizures at perceived risk, (3) prevention of seizure clusters. Standard ADA was 10 mg oral clobazam (CLB); one patient received 10 mg rectal diazepam. Concomitant antiepileptic drugs (AED) remained unchanged whenever possible. Ten patients used ADA always correctly, 7 mostly, 7 sporadically or not. Outcome considering seizure control was positive in 44% of all patients (59% of those who actually used ADA): 5 patients seizure free, 1 free of disabling seizures, 4 with >50% reduction in seizure frequency. Eleven had minor or no improvement, 3 patients could not be rated. Thirteen (of 19 possible) patients attempted prevention of seizures or clusters, 10 with full or >50% success (52.6 resp. 76.9%). Prevention of clusters sometimes required higher or repetitive CLB dosing. Self rating of patients who did use ADA was positive or very positive in 88.2%. Retention rate was 66.7% of all patients, and 88.2% of those using ADA. The best results were obtained in idiopathic generalized epilepsy (IGE) patients with seizures habitually triggered by typical factors (sleep deprival, alcohol) but also some others were successful. The only adverse effect was gait ataxia in a multiple-handicapped patient. ADA is an elegant and often successful but underused treatment option for selected patient groups where it can make the difference between becoming seizure free or not. Depending on the individual case it can be applied as monotherapy or in combination with a basis AED. A controlled investigation should follow.

PubMed Disclaimer

Conflict of interest statement

The author has no conflicts of interest to declare.

Similar articles

Cited by

References

    1. Shorvon SD. The use of clobazam, midazolam, and nitrazepam in epilepsy. Epilepsia 1998;39(Suppl 1):S15–S23. - PubMed
    1. Remy C. Clobazam in the treatment of epilepsy: A review of the literature. Epilepsia 1994;35(Suppl 5):S88–S91. - PubMed
    1. Feely M, Gibson J. Intermittent clobazam in catamenial epilepsy. Tolerance avoided. J Neurol Neurosurg Psychiatry 1984;47:1279–1282. - PMC - PubMed
    1. Foldvary‐Schaefer N, Falcone T. Catamenial epilepsy. Pathophysiology, diagnosis, and management. Neurology 2003;61:S2–S15. - PubMed
    1. Montenegro MA, Guerreiro CAM. Role of clobazam in the treatment of epilepsies. Expert Rev Neurother 2003;3:829–834. - PubMed